On February 19, 2018 BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), and Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), reported they will be presenting at two upcoming healthcare-focused investor conferences (Press release, Idera Pharmaceuticals, FEB 19, 2018, View Source [SID1234524650]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc.
The companies will be presenting at the RBC Capital Markets 2018 Global Healthcare Conference on Wednesday, February 21, 2018 at 3:05 P.M. E.T. The conference is being held at the Lotte New York Palace Hotel.
The companies will also be presenting at the 2018 Barclays Global Healthcare Conference on Tuesday, March 13, 2018 at 9:00 A.M. E.T. The conference is being held at the Lowes Miami Beach Hotel.
As a reminder, on January 22, 2018, BioCryst and Idera jointly announced the signing of a definitive merger agreement to combine into a company focused on the development and commercialization of medicines to serve patients suffering from rare diseases. At the upcoming conferences, the companies will discuss the strategic initiatives of both companies, and how the combination of the two companies is expected to capitalize on the collective expertise and combined assets to create a comprehensive, sustainable rare disease-focused biotechnology leader.
Live audio webcast of these presentations will be accessible in the Investors and Media section of Idera’s website at View Source and in the Investors section of BioCryst’s website at http://www.biocryst.com. Archived versions will also be available on the respective Company’s websites after the events for 90 days